Risk Factors for Poor Pain Control after Opioid Switching from Oxycodone Tablet to Fentanyl Patch.


Journal

Biological & pharmaceutical bulletin
ISSN: 1347-5215
Titre abrégé: Biol Pharm Bull
Pays: Japan
ID NLM: 9311984

Informations de publication

Date de publication:
2019
Historique:
entrez: 5 10 2019
pubmed: 5 10 2019
medline: 18 2 2020
Statut: ppublish

Résumé

Pain control becomes poor in some cases after opioid switching from oxycodone tablet (OXC) to fentanyl patch (FP). However, fewer studies on risk factors have been reported. In this study, we surveyed the states of pain control (PC) and opioid administration, patient background, laboratory test values, and concomitant drugs retrospectively in 86 patients switching from OXC to FP between June 2010 and April 2018 in Mazda Hospital and Hiroshima Prefectural Hospital. The subjects were divided into 2 groups based on the median number of days to the initial dose increase after switching to FP. Between the early (<7.5 d) and late (≥7.5 d) increase groups, a significant difference was noted in the presence or absence of liver metastasis (LM), concomitant drugs with a high protein binding rate (CDHPBR), and the state of PC before and after switching to FP (p < 0.05). Binary logistic regression analysis showed the presence of CDHPBR, absence of LM, and poor PC after switching were risk factors for early dose increase (presence of CDHPBR: odds ratios (OR), 3.30, 95% confidence interval (CI), 1.09-9.98; presence of LM: OR, 0.31, 95% CI, 0.10-0.93; good PC: OR, 0.23, 95% CI, 0.07-0.79, respectively). The initial dose increase after switching to FP was earlier in patients with CDHPBR and/or without LM than those without CDHPBR and with LM (p < 0.05, log-rank test). It was suggested that the analgesic effect of FP after switching from OXC is likely to be insufficient in patients treated with CDHPBR and patients without LM.

Identifiants

pubmed: 31582655
doi: 10.1248/bpb.b19-00271
doi:

Substances chimiques

Analgesics, Opioid 0
Tablets 0
Oxycodone CD35PMG570
Fentanyl UF599785JZ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1674-1678

Auteurs

Norimichi Morikawa (N)

Department of Pharmacy, Mazda Hospital of Mazda Motor Corporation.

Yoko Kasahara (Y)

Department of Pharmacy, Hiroshima Prefectural Hospital.

Yuko Takahashi (Y)

Department of Pharmacy, Mazda Hospital of Mazda Motor Corporation.

Kyoko Nishikura (K)

Department of Pharmacy, Mazda Hospital of Mazda Motor Corporation.

Masayuki Nishihara (M)

Department of Pharmacy, Mazda Hospital of Mazda Motor Corporation.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH